Lipedema, a Multifactorial Inflammatory Disease
Lipedema is a chronic adipose tissue disorder that predominantly affects women and is characterized by an abnormal and painful accumulation of subcutaneous fat, primarily in the lower extremities and, in some cases, the upper limbs. It is now recognized that lipedema is not merely a disorder of abnormal fat distribution, but rather a complex disease involving alterations in adipose tissue biology, microvascular dysfunction, and chronic low-grade inflammation, in which both external stimuli and immune cells infiltrating the adipose tissue contribute to the persistence of the inflammatory state.
Accumulation of adipose tissue
At GEK Lab, inflammatory status is assessed using specific biomarkers through the PerMè Recaller Program. Among these biomarkers is BAFF (B-cell Activating Factor), a cytokine involved in chronic low-grade inflammation. Elevated BAFF levels are associated with repetitive dietary habits (i.e., the frequent consumption of the same foods) or excessive food intake.
Several studies have shown that elevated BAFF levels promote the production of other pro-inflammatory cytokines, contribute to the development of insulin resistance, and modulate adipose tissue metabolism, thereby favoring the accumulation of adipose tissue, including the dense, inflamed fat that characterizes lipedema.
In a condition such as lipedema, which is characterized by pathological adipose tissue expansion together with persistent chronic inflammation and oxidative stress, reducing inflammatory and glycation-promoting stimuli through a personalized nutritional approach may represent an important supportive strategy in disease management.
MGO: Glycation and Microvascular Dysfunction
Another biomarker assessed through the PerMè Recaller Program is Methylglyoxal (MGO), a major marker of glycation associated with excessive or repetitive dietary sugar intake. Elevated MGO levels promote oxidative stress, damage the vascular endothelium, and impair microvascular function, leading to the increased production of pro-inflammatory mediators. These processes may contribute to extracellular fluid accumulation, a characteristic feature commonly observed in individuals with lipedema.
In lipedema, where microvascular dysfunction and increased capillary permeability are already present, excessive glycation may contribute to the persistence of edema and local inflammation. Therefore, reducing glycation and oxidative stress through a personalized anti-inflammatory dietary approach based on the results of the PerMè Recaller Program may provide valuable nutritional support as part of the overall management of lipedema.
Although this approach is not intended to resolve a condition with a well-recognized genetic and familial component, our clinical experience suggests that many patients who were initially considering supportive surgical procedures reported substantial clinical improvement following personalized nutritional intervention, in some cases postponing or avoiding more invasive treatment options.
We have been studying oxidative processes, glycation, and the effects of excessive sugar intake—including the similar metabolic effects of sweeteners, alcohol, and fructose—for many years.
Why Can an Anti-Inflammatory Diet Be Beneficial in Lipedema?
In lipedema, chronic low-grade inflammation, adipose tissue accumulation, microvascular dysfunction, and increased extracellular water (ECW) are closely interconnected. For this reason, a personalized anti-inflammatory dietary approach may represent an important component of the overall management of the disease.
By reducing individual inflammatory triggers and modulating glycation processes through the nutritional recommendations provided by the PerMè Recaller Program, it may be possible to reduce the inflammatory burden, improve microvascular health, and support the physiological function of the lymphatic system.
Furthermore, controlling chronic inflammation may contribute to improved body composition by promoting a reduction in overall fat mass while preserving metabolically active lean body mass.
The PerMè Recaller Program also assesses the presence of genetic predispositions to metabolic diseases, including type 2 diabetes, obesity, and metabolic dysfunction–associated steatotic liver disease (MASLD), providing a highly comprehensive and personalized nutritional approach tailored to each individual.
Conclusions
A personalized anti-inflammatory dietary approach based on the results of the PerMè Recaller Program represents an important nutritional strategy to support the management of lipedema. Current scientific evidence suggests that modulating chronic low-grade inflammation associated with repetitive dietary patterns and glycation may contribute to improving microvascular function, maintaining fluid balance, and promoting a healthier body composition.
